Medication is the default schizophrenia treatment; however, it may not address key symptoms like social and cognitive deficits. Group therapy may be a new, promising intervention.

Schizophrenia is the classic psychotic disorder and has long been considered the most severe form of mental illness. It is a problem that afflicts roughly 1 out of 100 people around the world. Since ...

CINCINNATI, Ohio. (Ivanhoe Newswire) - Schizophrenia, the statistics are terrifying. More than 3.7 million people are living with it right now in the United States. If left untreated it can be ...

For individuals diagnosed with schizophrenia, maintaining a daily medication routine can feel like an insurmountable challenge. The cognitive impairments associated with the disorder often interfere ...

Schizoaffective disorder and schizophrenia are separate mental disorders. Learn about both, including symptoms, risk factors, and treatment.

On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the ...

Long-acting injectables (LAIs) were designed to solve this problem by reducing the burden of daily pill-taking and ensuring more consistent drug exposure. Underutilization of LAIs in the U.S is common ...

A 33-year-old woman hears brutal and frightening voices daily but continues her college studies. A middle-aged man, who served in the Navy and has since struggled with substance abuse, spends 10 weeks ...

The panel provides their closing thoughts as they examine the stigmas and unmet needs surrounding schizophrenia. John J. Miller, MD: What do you view as the largest unmet need currently in treating ...

"About 10% of people with schizophrenia will engage in violence during their lifetimes, which is three to four times higher than the general population, but people with schizophrenia are more likely ...

Many people live with a secret that feels almost impossible to describe. They hear speech or whispers that nobody else ...

Neurocrine Biosciences Inc. plunged early Wednesday after a study of its experimental schizophrenia treatment was disappointing when compared to a rival medicine that’s likely to hit the market much ...